OPEN END TURBO LONG - BIOMERIEUX Share Price

Certificat

DE000MD24428

Real-time Bid/Ask 11:37:21 10/06/2024 BST
2.62 EUR / 2.64 EUR -2.23% Intraday chart for OPEN END TURBO LONG - BIOMERIEUX
Current month-10.63%
1 month-18.73%
Date Price Change
10/06/24 2.62 -2.60%
07/06/24 2.69 -4.61%
06/06/24 2.82 -1.74%
05/06/24 2.87 -0.69%
04/06/24 2.89 +0.35%

Delayed Quote Börse Stuttgart

Last update June 10, 2024 at 09:53 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BIOMÉRIEUX
Issuer Morgan Stanley
WKN MD2442
ISINDE000MD24428
Date issued 24/02/2022
Strike 66.67
Maturity Unlimited
Parity 10 : 1
Emission price 3.79
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.91
Lowest since issue 1.85
Spread 0.02
Spread %0.76%

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Sector
-
More about the company

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: bioMérieux

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
93.8 EUR
Average target price
113.5 EUR
Spread / Average Target
+20.98%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW